Nature's obstacles to xenotransplantation

Prolonged cardiac xenograft survival in guinea pig-to-rat model by a highly active cobra venom factor

A highly active cobra venom factor (CVF) was isolated from the venom of Naja kaouthia by sequential column chromatography. It displays strong anticomplementary activity, and has 1515 U of anticomplementary activity per mg protein. A single dose of 0.1 mg/kg CVF given i.v. to rats completely abrogated complement activity for nearly 5 days. Given 0.02 mg/kg of CVF, the complement activity of rats was reduced by more than 96.5% in 6 h. In guinea pig-to-rat heart transplant model, rats treated with a single dose of 0.05 mg/kg CVF had significantly prolonged xenograft survival (56.12+/-6.27 h in CVF-treated rats vs. 0.19+/-0.07 h in control rats, P<0.001).

Xenotransplantation: the good, the bad, and the ugly or how far are we to clinical application?

On the way to successful clinical XTP many obstacles have to be overcome, and new difficulties might still arise. For clinical XTP all "players of the concert" have to harmonize. It is not enough if one molecule is recognized by its receptor. A chain is only as strong as its weakest link; this is also true for xenogeneic immunology, physiology, and pharmacology. The phylogeneic distance between man and pig comprises 180 million years. This tremendous distance has to be bridged by new and still unknown methods to outwit evolution.

Physiologic incompatibilities in discordant xenotransplantation

At present, several incompatibilities between pig and human, not only from the immunologic point of view but also regarding physiological and molecular systems, have been identified. It is anticipated that this is only the tip of the iceberg regarding this topic. However, there are also many systems that are compatible. Strategies have been outlined, and many tools, such as gene modification, are available to solve the problems. Therefore, the statement by Keith Reemtsma in the foreward to the latest issue of the monography Xenotransplantation "The important question is not whether xenotransplantation will succeed, but rather how and under what circumstances xenografts will provide predictable enough results to warrent clinical application" will hopefully be a reality in the future.

The fourth barrier

At the entrance of a new era, clinical xenotransplantation is a valued and auspicious option in tackling the problem of donor shortage. Because of ethical and anatomical issues, domestic farm animals are considered the most favourable species for organ donation, but transplantation of their organs leads to a complex process of rejection. Mechanistically, three immunological barriers, namely hyperacute rejection, delayed xenograft rejection and a subsequent cellular rejection, are distinguished. A fifth (microbiological) barrier is also being recognised. This review focuses on problems regarding the fourth barrier, i.e. physiology, in possible clinical settings and their corresponding animal models. Besides anatomical differences and posture, biochemical differences may have a severe impact on recipient survival. Differences in blood components and electrolyte and other biochemical concentrations are easily detected throughout the species considered for xenotransplantation. Enzymes and hormones have complex routes of action, activation and inhibition, and their molecular differences can impede function. As infusion or medicine may correct certain imbalances in electrolytes and proteins, problems with complex interactions might be difficult to retrieve and solve. Experimentally, survival of discordant xenografts show promising results, but the first physiological problems have already been detected. So, based upon the few experimental data available and the comparison of veterinary physiology, one might expect differences between the organs grafted, regarding the possible occurrence of physiological problems. Moreover, precautions must be taken to extrapolate long-term survival, because of species specificity.

Morphology of hDAF (CD55) transgenic pig kidneys following ex-vivo hemoperfusion with human blood

Discordant xenotransplantation of pig kidneys into man may be possible in the future using transgenic organs which regulate complement activity. It was the aim of this experimental study to characterize morphologic alterations of organs transgenic for human decay accelerating factor (hDAF/CD55) perfused with human blood since no data on function of these organs after exposure to human blood are available. An ex-vivo system was developed that allows computer driven pressure-controlled perfusion of kidneys including a separate cartridge oxygenator circuit. Following cold ischemia time of 1-4 hr, 8 kidneys from heterozygote transgenic animals (TG) and 9 control kidneys (C) were perfused with 500 ml freshly drawn heparinized human blood at physiological conditions. A histologic grading system from 0 to +4 was used to describe the histologic findings. Using a mouse antihuman DAF moAB, hDAF was stained on all TG kidneys both on glomerular capillary (4+) and vascular endothelium (2+), but there was no detectable hDAF-expression on controls. No difference in xenoantibody deposition on vascular endothelium was seen between both groups. There was comparable staining for complement fraction C4 in both groups, but significant reduction of C3 and C9 staining on glomerular and vascular endothelium in TG. P-selectin was expressed on a higher level in C (+4) compared with TG (+2). Neutrophil extravasation [NP-57 elastase] was higher in C (80.2 vs. 32.2 C vs. TG [values as n/high power field]). Tubular epithelial cell swelling and mild necrosis was paralleled by glomerular hemorrhage and platelet microthrombus formation in both groups as seen in transmission electron microscopy. The observed results allow the conclusion that hDAF expression on transgenic pig kidneys was sufficient to inhibit complement activation beyond C3 during xenoperfusion with human blood despite xenoantibody deposition.

Na-K/2Cl transporter inhibition for reduction of postischemic kidney failure tested in autologous reperfusion

Postischemic kidney function may be influenced by donor conditioning. The sulfamoyl-benzoate "piretanide" (P) is a diuretic agent with an inhibitory effect on the luminal Na-K-2CL-transporter system in the ascending part of the loop of Henle. A clinical pilot study demonstrated a lower rate of organ dysfunction following transplantation in humans when the donor organs were pretreated with piretanide. In an experimental ex vivo model the effect of piretanide on immediate organ function following long or short cold ischemia was studied. Porcine kidneys (n = 36) were removed after in situ transaortal hypothermic flushing with 21 Eurocollins solution. Following short storage (1 h, n = 18) or long storage (24 h, n = 18) the kidneys were reperfused with intraoperatively drawn heparinized autologous blood diluted with Ringer's lactate to a hematocrit of 25%. Urine flow was higher in the piretanide-pretreated group (p), especially after long storage. The electrolyte loss was comparable in both groups. Postischemic endogenous creatinine clearance was significantly elevated in the treatment group (4.45 +/- 0.6 ml/min per 100 mg in P vs 1.91 +/- 0.4 ml/min per 100 mg, in control, P < 0.05 Mann-Whitney test). Renal hemodynamics were improved by piretanide, resulting in significantly lower resistance and allowing higher flow during pressure-controlled perfusion. O2 consumption, representing general metabolic activity, was higher after long storage, indicating an earlier recovery from cold ischemia. In this ex vivo model, autologous reperfusion of porcine kidneys could be improved by piretanide pretreatment. Autoregulation of kidney vasculature was maintained as well as functional parameters such as creatinine clearance or gluconeogenesis. Therefore, piretanide may be used in larger clinical trials to further improve organ quality in times of donor shortage.